Successful treatment of post-surgical osteomyelitis caused by XDR Pseudomonas aeruginosa with ceftolozane/tazobactam monotherapy
- 1 June 2017
- journal article
- case report
- Published by Oxford University Press (OUP) in Journal of Antimicrobial Chemotherapy
- Vol. 72 (9) , 2678-2679
Abstract
No abstract availableThis publication has 7 references indexed in Scilit:
- Ceftolozane/tazobactam activity against drug-resistant Enterobacteriaceae and Pseudomonas aeruginosa causing urinary tract and intraabdominal infections in Europe: report from an antimicrobial surveillance programme (2012–15)Journal of Antimicrobial Chemotherapy, 2017
- What is the role of the new β-lactam/β-lactamase inhibitors ceftolozane/tazobactam and ceftazidime/avibactam?Expert Review of Anti-infective Therapy, 2016
- Ceftolozane/Tazobactam: A Novel Cephalosporin/β-Lactamase Inhibitor Combination with Activity Against Multidrug-Resistant Gram-Negative BacilliDrugs, 2013
- Multidrug-resistant, extensively drug-resistant and pandrug-resistant bacteria: an international expert proposal for interim standard definitions for acquired resistanceClinical Microbiology and Infection, 2012
- Systemic Antibiotic Therapy for Chronic Osteomyelitis in AdultsClinical Infectious Diseases, 2011
- Monotherapy or Combination Therapy? The Pseudomonas aeruginosa ConundrumPharmacotherapy: The Journal of Human Pharmacology and Drug Therapy, 2011
- Nosocomial Infections Due to Multidrug‐Resistant Pseudomonas aeruginosa: Epidemiology and Treatment OptionsPharmacotherapy: The Journal of Human Pharmacology and Drug Therapy, 2005